FINWIRES · TerminalLIVE
FINWIRES

$NEO

5 stories mentioning NEOUpdated 4d ago

Every FINWIRES story that references NEO, newest first.

Wire

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.8%.The iShares Biotechnology ETF (IBB) shed 0.9%.In corporate news, Hims & Hers Health (HIMS) is being sued by the US Federal Trade Commission, the State of California, and the Utah Division of Consumer Protection, for allegedly sharing users' data with Meta (META), Snap (SNAP) and other online advertising companies, court documents show. Hims & Hers Health shares fell past 14%.UnitedHealth (UNH) may lose significant funding as the Trump administration plans to terminate a Medicare prescription drug subsidy program, The Wall Street Journal reported. The government will end the $3.6 billion subsidy after 2026, which would have directed more than half of its funds to UnitedHealth next year, the report quoted the administration officials as saying. UnitedHealth shares were down 1.8%.Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, citing factors including weak demand for its Watchman heart implant. Its shares were down 1.5%.NeoGenomics (NEO) shares jumped past 15% after it reported better-than-expected Q2 results.

$BSX$HIMS$NEO$UNH
Wire

Sector Update: Healthcare

Healthcare stocks were mixed late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.4%.The iShares Biotechnology ETF (IBB) eased 0.1%.In corporate news, NeoGenomics (NEO) shares jumped past 17% after it reported better-than-expected Q2 results.

$NEO
Wire

Update: NeoGenomics Shares Rise After Q2 Beat

(Updates with the latest stock movement in the first paragraph and headline.)NeoGenomics (NEO) shares were up over 15% in Wednesday trading following its better-than-expected Q2 results.Late Tuesday, the company reported Q2 adjusted earnings of $0.05 per diluted share, up from $0.03 a year earlier.Analysts polled by FactSet expected $0.03.Revenue for the quarter ended June 30 was $201.7 million, up from 181.3 million a year earlier.Analysts expected $196.9 million.The company said it now expects 2026 revenue of $802 million to $806 million, up from its prior range of $797 million to $803 million. Analysts expect $800.4 million.Price: $15.51, Change: $+2.11, Percent Change: +15.75%

$NEO
Treasury

NeoGenomics Reports Convertible Notes Offering

NeoGenomics (NEO) said late Monday it has launched an offering of $275 million of convertible senior notes due 2032.The company said it plans to grant the initial buyers a 13-day option to buy up to $41.25 million of additional notes.

$NEO
Research

Leerink Upgrades NeoGenomics to Outperform From Market Perform, Adjusts Price Target to $25 From $12

NeoGenomics (NEO) has an average rating of overweight and mean price target of $14.61, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$NEO

Track with the FINWIRES app suite